PERTH, Australia – Australian cell therapy developer Mesoblast Ltd. has partnered with Germany's Grünenthal Group to develop and commercialize Mesoblast's allogeneic cell therapy candidate, MPC-06-ID, in a deal that carves out Europe, Latin America and the Caribbean.

PERTH, Australia – Stem cell therapy has failed to deliver on its promises, according to Exopharm Ltd. founder and CEO Ian Dixon, who said he believes that exosomes, or the extracellular vesicles released by stem cells, could be a disrupter in the regenerative medicine space.

PERTH, Australia – Stem cell therapy has failed to deliver on its promises, according to Exopharm Ltd. founder and CEO Ian Dixon, who said he believes that exosomes, or the extracellular vesicles released by stem cells, could be a disrupter in the regenerative medicine space.

PERTH, Australia – There is pervasive use of artificial intelligence and machine learning (AI/ML) across the health care industry in Australia, and excitement is building on the opportunities it offers to technologies and ultimately to patients, Ausbiotech CEO Lorraine Chiroiu told BioWorld.

PERTH, Australia – It's likely that Australia will not draft separate guidance or regulations for software applications that use artificial intelligence or machine learning (AI/ML) for drug development or medical devices.

PERTH, Australia – It's likely that Australia will not draft separate guidance or regulations for software applications that use artificial intelligence or machine learning (AI/ML) for drug development or medical devices. Instead, the Therapeutic Goods Administration (TGA) will classify AI and ML under software as a medical device (SaMD) when it is intended for diagnosis, prevention, monitoring or treatment or alleviation of disease.

PERTH, Australia – It's likely that Australia will not draft separate guidance or regulations for software applications that use artificial intelligence or machine learning (AI/ML) for drug development or medical devices.